Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3
- Registration Number
- NCT01296568
- Locations
- 🇨🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bruderholz, Switzerland
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Biological: IMC-3C5
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT01288989
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States
A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT01287520
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States
A Study of LY2875358 in Participants With Advanced Cancer
- Conditions
- Advanced Cancer
- Interventions
- Drug: LY2875358 at Part A highest doseDrug: LY2875358 at Part A highest dose + trametinib
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT01287546
- Locations
- 🇺🇸
University of California - San Diego, La Jolla, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01286818
- Locations
- 🇯🇵
ImClone Investigational Site, Shizuoka, Japan
A Safety Study in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 234
- Registration Number
- NCT01284335
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yakima, Washington, United States
A Study of LY2801653 in Advanced Cancer
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 190
- Registration Number
- NCT01285037
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
- Conditions
- Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of UreterCarcinoma of Renal Pelvis
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT01282463
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada
Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01275157
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of the Effect of LY2216684 on Lorazepam
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01275144
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Leeds, United Kingdom